COMMUNIQUÉS West-GlobeNewswire

Insmed to Host Second Quarter 2018 Financial Results Conference Call on Thursday, August 2, 2018
26/07/2018
BRIDGEWATER, N.J., July 26, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release [...]
Progressive Care Subsidiary PharmCo Partners with Westchester General Hospital to Implement New DischargeRx Program
26/07/2018
MIAMI, July 26, 2018 (GLOBE NEWSWIRE) -- Progressive Care Inc. (OTCQB:RXMD), a personalized healthcare services and technology company, today announced a partnership with Westchester General Hospital to implement [...]
Spine Injury Solutions Inc. (SPIN) Expands Its Affiliate Spine Diagnostic Practices To Include Concussion/Traumatic Brain Injury (TBI) Testing
26/07/2018
HOUSTON, July 26, 2018 (GLOBE NEWSWIRE) -- Spine Injury Solutions, Inc. (OTCQB:SPIN), a technology-driven, medical service, financing and healthcare solution company announces after three months of research and testing [...]
aTyr Pharma Presents Positive Lung and Skin Findings with ATYR1923 in a Translational Animal Model at the Scleroderma Foundation National Patient Education Conference
26/07/2018
SAN DIEGO, July 26, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today [...]
Extendicare Announces Pending Departure of CEO
26/07/2018
MARKHAM, Ontario, July 26, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX:EXE) today announced that Tim Lukenda will be stepping down from his position as President and CEO, and Director [...]
Tetra Bio-Pharma Confirms Meetings With FDA
26/07/2018
Type B & C Meetings Move TBP Closer to Market Approval ORLEANS, Ontario, July 26, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc ., (“ Tetra ” or the “ Company ”) a leader in cannabinoid-based drug discovery and [...]
Kalytera Therapeutics Announces Filing of Amended and Restated Short Form Prospectus
26/07/2018
/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/ SAN FRANCISCO and TEL AVIV, Israel, July 26, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (the "Company", or “Kalytera”) (TSXV:KALY [...]
ADMA Biologics Receives PDUFA Date for BIVIGAM® Regulatory Submission
26/07/2018
Prior Approval Supplement (“PAS”) to Amend the Biologics License Application (“BLA”) for BIVIGAM ® is Supported by Data and Documentation Prepared Using ADMA’s Optimized IVIG Manufacturing P rocess Demonstrating Robust [...]
Inovalon Achieves Significant Advancement in Cloud Computing Capabilities
26/07/2018
Company Develops and Deploys Highly Elastic Cloud Container Orchestration Engine BOWIE, Md., July 26, 2018 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq:INOV), a leading technology company providing advanced, cloud-based [...]
Otonomy Initiates Phase 3 Clinical Trial of OTIVIDEX™ in Ménière’s Disease
26/07/2018
SAN DIEGO, July 26, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced initiation of the additional [...]
Abiomed Announces Approval in India for the Impella 2.5®, Impella CP® and Impella 5.0® Heart Pumps and First Indian Patient Treated
26/07/2018
DANVERS, Mass., July 26, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart recovery and support technologies, announced the Impella 2.5 ® , Impella CP ® and Impella 5.0 ® [...]
Emblem Corp. Signs Letter of Intent to Acquire Natura Naturals
26/07/2018
Acquisition adds up to 70,000kg/yr capacity to support aggressive growth plan TORONTO, July 26, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV:EMC) (OTCBB:EMMBF) (“Emblem” or the “Company”), announced today that it has [...]
Pain Therapeutics Reports Second Quarter 2018 Financial Results
26/07/2018
AUSTIN, Texas, July 26, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a drug development company, today reported financial results for the second quarter ended June 30, 2018. Net loss was $2.5 million [...]
Asterias Biotherapeutics to Report Second Quarter 2018 Results on August 9, 2018
26/07/2018
FREMONT, Calif., July 26, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated [...]
Athenex Announces That Two Phase 3 Pivotal Efficacy Studies of KX2-391 in Actinic Keratosis Achieved Their Primary Endpoints
26/07/2018
BUFFALO, N.Y., July 26, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
Aclaris Therapeutics to Announce Second Quarter 2018 Financial Results on August 3, 2018
26/07/2018
WAYNE, Pa., July 26, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to [...]
Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018
26/07/2018
- Initiation of Phase 1, first-in-human clinical trial of MCLA-158 in patients with solid tumors - - MCLA-128’s unique mechanism of action published in the scientific journal Cancer Cell - UTRECHT, The Netherlands, July [...]
Abiomed Announces Q1 FY 2019 Record Revenue of $180 Million, Up 36% Over Prior Year
26/07/2018
Completed Enrollment for the FDA STEMI DTU Safety and Feasibility Study DANVERS, Mass., July 26, 2018 (GLOBE NEWSWIRE) -- ABIOMED, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart recovery and support [...]
VBI Vaccines Announces Second Quarter 2018 Financial Results and Provides Corporate Update
26/07/2018
-- Pivotal Phase 3 program for Sci-B-Vac ® Hepatitis B vaccine continues to advance towards topline data expected mid-year 2019 -- -- Positive safety and immunogenicity data from Phase 1 study of VBI-1501 for Congenital [...]

Pages